DS
FPRX

David Shaw’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

David Shaw’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-350,212
Closed -$1.65M – 4278
2020
Q3 		$1.65M Sell
350,212
-17,575
-5% -$89.3K ﹤0.01% 2526
2020
Q2 		$2.24M Buy
367,787
+114,890
+45% +$473K ﹤0.01% 2327
2020
Q1 		$575K Sell
252,897
-33,199
-12% -$141K ﹤0.01% 3138
2019
Q4 		$1.31M Buy
286,096
+93,402
+48% +$370K ﹤0.01% 2791
2019
Q3 		$747K Buy
192,694
+106,048
+122% +$582K ﹤0.01% 2998
2019
Q2 		$522K Buy
86,646
+71,703
+480% +$686K ﹤0.01% 3056
2019
Q1 		$200K Sell
14,943
-100
-0.7% -$1.14K ﹤0.01% 3406
2018
Q4 		$140K Buy
+15,043
New +$179K ﹤0.01% 3604
2018
Q3 		– Sell
-15,157
Closed -$240K – 4075
2018
Q2 		$240K Buy
+15,157
New +$264K ﹤0.01% 3477
2018
Q1 		– Sell
-21,913
Closed -$480K – 3885
2017
Q4 		$480K Buy
21,913
+1,467
+7% +$47.2K ﹤0.01% 3002
2017
Q3 		$837K Buy
20,446
+1,978
+11% +$62.1K ﹤0.01% 2602
2017
Q2 		$556K Sell
18,468
-1,393
-7% -$43.5K ﹤0.01% 2765
2017
Q1 		$718K Sell
19,861
-25,331
-56% -$1.12M ﹤0.01% 2532
2016
Q4 		$2.26M Sell
45,192
-42,723
-49% -$2.24M ﹤0.01% 1904
2016
Q3 		$4.62M Buy
87,915
+15,716
+22% +$750K 0.01% 1345
2016
Q2 		$2.98M Sell
72,199
-101,624
-58% -$4.42M 0.01% 1634
2016
Q1 		$7.06M Sell
173,823
-89,195
-34% -$3.07M 0.01% 1058
2015
Q4 		$10.9M Buy
263,018
+206,628
+366% +$6.93M 0.02% 933
2015
Q3 		$868K Sell
56,390
-146,369
-72% -$3.15M ﹤0.01% 2697
2015
Q2 		$5.04M Sell
202,759
-56,390
-22% -$1.26M 0.01% 1460
2015
Q1 		$5.92M Buy
259,149
+189,409
+272% +$4.78M 0.01% 1269
2014
Q4 		$1.88M Buy
+69,740
New +$1.2M ﹤0.01% 2330

Other funds holding FPRX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

David Shaw's FPRX Position: Q4 2020 in Review

David Shaw sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 350,212 shares — an estimated $1.65M sold.

David Shaw first reported a position in FPRX in Q4 2014 and held it in 22 quarters. The position peaked at $10.9M in Q4 2015. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

  • David Shaw reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • David Shaw sold 350,212 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $1.65M.
  • David Shaw first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 22 quarters.
  • David Shaw's Five Prime Therapeutics, Inc. position peaked at $10.9M in Q4 2015.
  • 125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on D.E. Shaw & Co's 13F filing for Q4 2020, filed 16 Feb 2021.